MiNK Therapeutics
INKT
18 hedge funds and large institutions have $1.28M invested in MiNK Therapeutics in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.
177% more capital invested
Capital invested by funds: $461K → $1.28M (+$818K)
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0.47% more ownership
Funds ownership: 1.55% → 2.02% (+0.47%)
5% less funds holding
Funds holding: 19 → 18 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$234K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$154K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$85.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$21K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$14.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$18K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$6.27K |
| 3 |
TIM
Total Investment Management
Scottsdale,
Arizona
|
-$3.69K |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
-$236 |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$160 |
INKT Hedge Fund Activity: Q3 2025 in Review
18 institutional investors reported a position in MiNK Therapeutics (INKT) for Q3 2025, worth a combined $1.28M — up 177% from $461K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of INKT and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $234K. The largest seller was BlackRock, cutting an estimated $18K.
- 18 institutional investors held MiNK Therapeutics (INKT) as of Q3 2025, down from 19 in Q2 2025.
- Funds reported $1.28M of MiNK Therapeutics stock for Q3 2025, up 177% quarter-over-quarter.
- 2 funds opened new MiNK Therapeutics positions in Q3 2025 and 3 closed out, a net change of -1 holder.
- The largest MiNK Therapeutics buyer in Q3 2025 was Renaissance Technologies, an estimated $234K added.
- The largest MiNK Therapeutics seller in Q3 2025 was BlackRock, an estimated $18K sold.
Based on aggregated 13F filings for Q3 2025.